

# A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

NCT07199270

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Enrollment	64 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Healthy adult subjects
- Signed informed consent

### Exclusion (4)

- History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
- Prior use of drug targeting TNF-like cytokine 1A
- history of malignant tumor
- psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)

## Locations (1 total)

---

Beijing Friendship hospital, Capital Medical University, Beijing, Beijing Municipality, China